Assessing An Oral Janus Kinase Inhibitor AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

  • End date
    Nov 30, 2022
  • participants needed
  • sponsor
    Dizal Pharmaceuticals
Updated on 30 May 2021
Jason Li, MD
Primary Contact
Chonbuk National University Hospital (0.0 mi away) Contact
+21 other location
systemic therapy
measurable disease
t-cell lymphoma
peripheral t-cell lymphoma


This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients with peripheral T cell lymphoma (PTCL), who have relapsed from or are refractory/intolerant to standard systemic treatment.

Phase 1 part:

Around 20~40 patients will be subsequently enrolled into 2 different dose ascending cohorts. Additional 10~20 patients may be enrolled to further explore a selected dose defined by dose escalation cohorts.

Phase 2 part:

After the recommended phase 2 dose (RP2D) is defined, a phase 2 single-arm open-label pivotal study will be conducted to assess anti-tumor efficacy and safety of AZD4205 at RP2D in patients with refractory or relapsed PTCL.

Condition Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Relapsed or Refractory Peripheral T Cell Lymphoma
Treatment AZD4205
Clinical Study IdentifierNCT04105010
SponsorDizal Pharmaceuticals
Last Modified on30 May 2021


Yes No Not Sure

Inclusion Criteria

Obtained written informed consent
Patients must have histologically confirmed peripheral T-cell lymphoma according to the 2016 revision of the World Health Organization classication of lymphoid neoplasms. Tumor samples are required for central pathology review to confirm the diagnosis
Patients must have measurable disease according to the Lugano criteria
Patients should be transplant-ineligible upon their entry into this study, and must have relapsed after or been refractory/intolerant to 1 (but not > 3) prior systemic therapy(ies) for PTCL
Adequate bone marrow reserve and organ system functions

Exclusion Criteria

Any unsolved toxicity > Common Terminology Criteria for Adverse Events (CTCAE) grade 1 from previous anti-cancer therapy (except alopecia)
Active infections, active or latent tuberculosis
Patients with severely decreased lung function
History of heart failure or QT interval prolongation
Central nervous system (CNS) or leptomeningeal lymphoma
History of treatment with Janus kinase (JAK) or signal transducer and activator of transcription 3 (STAT3) inhibitor
Patient has undergone an allogeneic stem cell transplant. Patient had autologous stem cell transplant within 6 months
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note